The global biliary stents market size was estimated to be USD 146.4 million in 2023 and is expected to reach USD 256.5 million by 2034 with a CAGR of 5.23% during the forecast period 2024-2034. Increasing incidence of biliary diseases, technological advancements, increasing awareness and diagnostic capabilities, growing demand for minimally invasive procedures, government initiatives and reimbursement policies, and partnerships and collaborations will drive the market growth.
Biliary illnesses such as gallstones, bile duct cancer, and pancreatitis are becoming more common. This is attributable to a combination of causes, including an aging population, obesity, and dietary changes. Biliary stents are frequently utilized to treat biliary disorders in minimally invasive treatments. These techniques are less intrusive than regular surgery and need less time to recuperate. This has boosted the need for biliary stents. For instance, Boston Scientific announced the debut of their latest generation of biliary stents, the Lumina Flex biliary stent system, in October 2023. The Lumina Flex stent is intended to improve bile duct access and stent insertion by providing increased flexibility and conformability.
By type, the metal biliary stents segment accounted for the highest revenue-grossing segment in the global biliary stents market in 2023 owing to the innovative design improvements, increased durability, and enhanced biocompatibility of metal biliary stents, which have significantly contributed to their widespread adoption among healthcare professionals. For instance, Cook Medical got FDA clearance for their Axios Biliary Stent System in September 2023. The Axios stent is intended to enable long-term biliary drainage and is comprised of a biocompatible polymer that is less prone to induce irritation or inflammation. Additionally, the polymer stents segment is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in polymer technology, offering greater flexibility, reduced risk of migration, and improved patient comfort. The increasing focus on developing biodegradable and drug-eluting polymer stents has garnered significant attention, fostering their adoption for various biliary indications.
By application, the gallstones segment accounted for the highest revenue-grossing segment in the global biliary stents market in 2023 owing to the escalating incidence of gallstone-related complications and biliary obstructions, necessitating the widespread deployment of biliary stents for effective treatment. For instance, in August 2023, Medtronic announced the purchase of ENGEOTEC, a developer of new biliary drainage treatments. The acquisition will broaden Medtronic's line of biliary stents and accessories. Additionally, the benign biliary structures segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding applications of biliary stents in the management of benign biliary strictures arising from various causes such as postoperative complications, chronic pancreatitis, and inflammatory conditions.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global biliary stents market in 2023 owing to the rising prevalence of complex biliary diseases requiring advanced medical interventions and the increasing adoption of biliary stenting procedures in hospital settings. For instance, C.R. Bard announced the release of their innovative ViziFlex Biliary Stent System in July 2023. The ViziFlex stent is intended to increase visibility under fluoroscopy, allowing clinicians to implant the stent more precisely. Additionally, the ambulatory surgical centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend toward outpatient procedures, advancements in minimally invasive techniques, and the convenience and cost-effectiveness offered by ambulatory surgical centers (ASCs).
North American region is anticipated for the highest revenue share during the forecast period owing to the high prevalence of biliary disorders, well-established healthcare infrastructure, and early adoption of advanced medical technologies in the North American region. Additionally, favorable reimbursement policies, increased awareness among healthcare professionals, and a growing aging population contribute to the strong market position. For instance, Abbott Laboratories announced the introduction of its innovative Amplatz Biliary Stent System in June 2023. The Amplatz stent is comprised of a biocompatible material that is less prone to induce irritation or inflammation and is intended to offer long-term biliary drainage. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of biliary diseases, a rapidly expanding healthcare sector, and a growing emphasis on improving medical infrastructure and accessibility in the Asia Pacific region. Rising healthcare awareness, a large and aging population, and a surge in healthcare spending contribute to the region's potential for robust growth in the biliary stents market.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Biliary illnesses such as gallstones, bile duct cancer, and pancreatitis are becoming more common. This is attributable to a combination of causes, including an aging population, obesity, and dietary changes. Biliary stents are frequently utilized to treat biliary disorders in minimally invasive treatments. These techniques are less intrusive than regular surgery and need less time to recuperate. This has boosted the need for biliary stents. For instance, Boston Scientific announced the debut of their latest generation of biliary stents, the Lumina Flex biliary stent system, in October 2023. The Lumina Flex stent is intended to improve bile duct access and stent insertion by providing increased flexibility and conformability.
By type, the metal biliary stents segment accounted for the highest revenue-grossing segment in the global biliary stents market in 2023 owing to the innovative design improvements, increased durability, and enhanced biocompatibility of metal biliary stents, which have significantly contributed to their widespread adoption among healthcare professionals. For instance, Cook Medical got FDA clearance for their Axios Biliary Stent System in September 2023. The Axios stent is intended to enable long-term biliary drainage and is comprised of a biocompatible polymer that is less prone to induce irritation or inflammation. Additionally, the polymer stents segment is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in polymer technology, offering greater flexibility, reduced risk of migration, and improved patient comfort. The increasing focus on developing biodegradable and drug-eluting polymer stents has garnered significant attention, fostering their adoption for various biliary indications.
By application, the gallstones segment accounted for the highest revenue-grossing segment in the global biliary stents market in 2023 owing to the escalating incidence of gallstone-related complications and biliary obstructions, necessitating the widespread deployment of biliary stents for effective treatment. For instance, in August 2023, Medtronic announced the purchase of ENGEOTEC, a developer of new biliary drainage treatments. The acquisition will broaden Medtronic's line of biliary stents and accessories. Additionally, the benign biliary structures segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding applications of biliary stents in the management of benign biliary strictures arising from various causes such as postoperative complications, chronic pancreatitis, and inflammatory conditions.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global biliary stents market in 2023 owing to the rising prevalence of complex biliary diseases requiring advanced medical interventions and the increasing adoption of biliary stenting procedures in hospital settings. For instance, C.R. Bard announced the release of their innovative ViziFlex Biliary Stent System in July 2023. The ViziFlex stent is intended to increase visibility under fluoroscopy, allowing clinicians to implant the stent more precisely. Additionally, the ambulatory surgical centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend toward outpatient procedures, advancements in minimally invasive techniques, and the convenience and cost-effectiveness offered by ambulatory surgical centers (ASCs).
North American region is anticipated for the highest revenue share during the forecast period owing to the high prevalence of biliary disorders, well-established healthcare infrastructure, and early adoption of advanced medical technologies in the North American region. Additionally, favorable reimbursement policies, increased awareness among healthcare professionals, and a growing aging population contribute to the strong market position. For instance, Abbott Laboratories announced the introduction of its innovative Amplatz Biliary Stent System in June 2023. The Amplatz stent is comprised of a biocompatible material that is less prone to induce irritation or inflammation and is intended to offer long-term biliary drainage. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of biliary diseases, a rapidly expanding healthcare sector, and a growing emphasis on improving medical infrastructure and accessibility in the Asia Pacific region. Rising healthcare awareness, a large and aging population, and a surge in healthcare spending contribute to the region's potential for robust growth in the biliary stents market.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Biliary Stents Market Report 2023 - 2034
Biliary Stents Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Mn)
- Metal
- Polymer
- Plastic
Biliary Stents Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Mn)
- Biliopancreatic Leakages
- Pancreatic Cancer
- Benign Biliary Structures
- Gallstones
- Others
Biliary Stents Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Mn)
- Hospitals
- Ambulatory Surgical Centers
- Others
Biliary Stents Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Mn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Microneedle Flu Vaccine Market: Type Estimates & Trend Analysis
8. Microneedle Flu Vaccine Market: Application Estimates & Trend Analysis
9. Microneedle Flu Vaccine Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Microneedle Flu Vaccine Market
12. Europe Global Microneedle Flu Vaccine Market
13. Asia Pacific Global Microneedle Flu Vaccine Market
14. Latin America Global Microneedle Flu Vaccine Market
15. MEA Global Microneedle Flu Vaccine Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Boston Scientific Corporation
- Cook Medical
- Medtronic plc
- C.R. Bard (acquired by BD)
- Abbott Laboratories
- EndoChoice Inc. (acquired by Boston Scientific)
- CONMED Corporation
- Taewoong Medical Co. Ltd.
- Micro-Tech (Nanjing) Co. Ltd.
- Merit Medical Systems Inc.
- Terumo Corporation
- ELLA-CS s.r.o.
- Optimed Medizinische Instrumente GmbH
- Ella-CS s.r.o.
- Becton
- Dickinson and Company (BD).
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 146.4 Million |
| Forecasted Market Value ( USD | $ 256.5 Million |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
